Roche Holding AG (SWX:ROP)
334.50
+4.10 (1.24%)
May 22, 2026, 5:30 PM CET
Roche Holding AG Revenue
In the year 2025, Roche Holding AG had annual revenue of 63.36B CHF with 1.54% growth. Roche Holding AG had revenue of 31.51B in the half year ending December 31, 2025, with 5.64% growth.
Revenue
63.36B
Revenue Growth
+1.54%
P/S Ratio
4.21
Revenue / Employee
613.62K
Employees
103,249
Market Cap
266.66B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 63.36B | 961.00M | 1.54% |
| Dec 31, 2024 | 62.40B | 1.95B | 3.23% |
| Dec 31, 2023 | 60.44B | -5.37B | -8.16% |
| Dec 31, 2022 | 65.81B | -36.00M | -0.05% |
| Dec 31, 2021 | 65.85B | 5.51B | 9.13% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Novartis AG | 45.38B |
| Sandoz Group AG | 8.85B |
| Alcon | 8.53B |
| Lonza Group AG | 6.53B |
| Galderma Group AG | 4.16B |
| Galenica AG | 4.15B |
| Sonova Holding AG | 3.61B |
| Straumann Holding AG | 2.61B |
Roche Holding AG News
- 4 days ago - Genentech to Present New Data at ASCO 2026, Reinforcing Giredestrant's Potential to Transform the Treatment Paradigm in Early Breast Cancer - Business Wire
- 4 days ago - Roche to present new data at ASCO 2026, reinforcing giredestrant's potential to transform the treatment paradigm in early breast cancer - GlobeNewsWire
- 4 days ago - Roche, Medicines Patent Pool sign deal to expand access to influenza drug - Reuters
- 7 days ago - FDA approves Genentech’s Tecentriq for adjuvant muscle-invasive bladder cancer - TheFly
- 7 days ago - FDA Approves Genentech's Tecentriq for Adjuvant Muscle-Invasive Bladder Cancer With ctDNA-Guided Treatment - Business Wire
- 10 days ago - Roche CEO Expects Pharma Portfolio to Deliver Sales Growth Through 2030 - WSJ
- 10 days ago - Roche receives CE Mark for Elecsys pTau217 - TheFly
- 10 days ago - Roche Holding AG Transcript: Roche Diagnostics Day 2026 - Transcripts